Lunaphore Technologies S.A., a pioneering Swiss-based life sciences company and brand under Bio-Techne, recently announced a significant funding milestone, successfully raising $169.7 million in its latest investment round. Founded in 2014, Lunaphore has been at the forefront of advancing spatial biology, striving to make this revolutionary technology accessible in every laboratory. The company has developed a groundbreaking chip technology that allows researchers to extract and analyze spatial proteomic and genomic data directly from tumors, revolutionary in transforming standard assays into multiplex spatial biology endeavors with unprecedented ease and accuracy. This latest influx of funding will be instrumental in accelerating Lunaphore's mission to empower researchers across the globe to overcome existing limitations in biological research, ultimately leading to the innovation of next-generation personalized therapies. With these resources, Lunaphore plans to enhance its product offerings and expand its global reach, fostering collaborations that will further enrich scientific understanding in the field of oncology and beyond. As the life sciences landscape continues to evolve, Lunaphore remains committed to pushing the boundaries of research and driving advancements that will significantly benefit patients in need of tailored therapeutic solutions. This investment serves as a testament to the growing confidence in Lunaphore's vision and technology, positioning the company as a key player within the spatial biology domain.





